There is a molecule your body has been producing since before you were born that kills bacteria, viruses, fungi, and spores with a precision and efficiency that no commercially manufactured disinfectant has matched. It is non-toxic at the concentrations required for that killing. It leaves no persistent residue. It does not generate microbial resistance. It degrades into water and trace saline when its work is done.
Your immune system has been using it for hundreds of millions of years.
The chemical industry has spent the past century selling you something else.
This is not a conspiracy. It is something more ordinary and in some ways more troubling — a century of technological substitution driven not by what worked best for the human body but by what could be manufactured, stabilized, patented, and sold at scale within the industrial infrastructure that existed at the time. The alternatives that filled that infrastructure were not chosen because they were superior to what the body already knew. They were chosen because they were available. The molecule the body already knew was not, until recently, manufacturable at the scale and stability that commercial distribution requires.
That has changed.
Understanding how and why requires understanding what the immune system actually does — and what a century of industrial chemistry substituted for it.
What the Neutrophil Knows
When a bacterium penetrates the body’s physical barriers — the skin, the mucous membranes, the epithelial layers that separate the body’s interior from the world — the first responders are neutrophils. These are the most abundant white blood cells in the human body, produced in the bone marrow at a rate of approximately one hundred billion per day, deployed to sites of infection within minutes of a breach, and designed for one primary purpose: the destruction of pathogens.
The neutrophil destroys pathogens through a process called the oxidative burst. Upon contact with a bacterium, the neutrophil engulfs it, sealing the bacterium inside a membrane-enclosed compartment called a phagosome. Inside the phagosome, the neutrophil deploys its arsenal. The primary weapon is hypochlorous acid — HOCl — synthesized from hydrogen peroxide and chloride ions by the enzyme myeloperoxidase.
The concentration of HOCl inside the phagosome at the moment of deployment is sufficient to kill most bacteria within milliseconds. The mechanism is the broad-spectrum oxidative disruption of the bacterium’s cellular structures — the cell wall, the membrane proteins, the enzymatic machinery, the DNA. The disruption is not targeted at a specific metabolic pathway. It is an assault on the fundamental integrity of the bacterial cell.
This is why bacteria cannot develop resistance to HOCl in the way they develop resistance to antibiotics. Antibiotic resistance requires the evolution of a specific countermeasure to a specific mechanism of interference. HOCl does not interfere with a specific mechanism. It dismantles the structure. There is no specific countermeasure available to a cell whose structural integrity is being oxidatively destroyed.
The immune system arrived at this solution through hundreds of millions of years of selection pressure — the accumulated evolutionary optimization of a system that had to kill an enormous diversity of pathogens quickly, reliably, and without damaging the surrounding tissue of the organism it was protecting. HOCl was the solution that selection retained. Every other approach was discarded.
This is not a trivial endorsement. Evolution is the most rigorous selection process available. What it retains across hundreds of millions of years of continuous testing against every pathogen a vertebrate immune system has encountered is the best available solution to the problem being solved — not the most elegant, not the most intellectually satisfying, but the most reliably effective under the conditions of actual use.
The human body’s primary antimicrobial molecule is HOCl.
What the Industry Sold Instead
The history of commercial disinfection is a history of technological substitution — the replacement of the body’s own solution with alternatives that were not chosen for their superiority but for their manufacturability within the industrial infrastructure of their time.
Chlorine-based disinfectants — household bleach, sodium hypochlorite solutions — were the first industrial-scale disinfection products. Sodium hypochlorite releases HOCl in water, which is why it works. But the alkaline pH at which sodium hypochlorite is stable — typically pH 11 to 13 — produces a solution in which most of the active compound exists as hypochlorite ion (OCl⁻) rather than HOCl. At pH 11, approximately 99.7% of the available chlorine is in the less active OCl⁻ form. The molecule that actually kills — HOCl — exists in high concentrations only at pH 5 to 6.5. Bleach solutions achieve disinfection, but at concentrations far higher than the HOCl concentration required, with the irritation, corrosivity, and tissue toxicity that high-concentration alkaline solutions produce.
The body does not use sodium hypochlorite. The body uses HOCl at slightly acidic pH — the precise condition of maximum biological activity. The industrial product approximates the outcome through a different and less elegant mechanism at a higher cost in toxicity and concentration.
Alcohol-based disinfectants — isopropanol, ethanol — work through protein denaturation and membrane disruption. They are effective against many bacteria and enveloped viruses, deployable without water, and fast-acting. They are also flammable, drying to skin at repeated use concentrations, ineffective against non-enveloped viruses and bacterial spores, and dependent on continuous evaporation for their mechanism of action — which means their efficacy window is brief and their residual effect is essentially zero.
The body does not use alcohol. The body has no alcohol-based antimicrobial system. Alcohol disinfection is an industrial invention with a specific and useful but limited profile — not a superior alternative to what the body already does, but a different tool for different circumstances that was adopted because it was manufacturable, stable at room temperature, and effective enough for the contexts in which it was used.
Quaternary ammonium compounds — quats — are positively charged surfactants that disrupt bacterial cell membranes through electrostatic interaction. They are effective against many bacteria and some viruses, stable at room temperature, and non-volatile. They are also increasingly associated with the development of microbial tolerance — not classical antibiotic resistance, but reduced susceptibility that accumulates with repeated sub-lethal exposure. They are toxic to aquatic organisms, persistent in the environment, and their safety profile at occupational exposure levels has been the subject of increasing regulatory scrutiny.
The body does not use quaternary ammonium compounds. There is no quat-producing immune mechanism. These compounds were developed for industrial surface disinfection and cleaning because they were manufacturable, stable, and effective at concentrations that could be incorporated into commercial cleaning products. They were adopted not because they were what the body would have chosen but because they were what the manufacturing infrastructure could produce.
Why the Body’s Solution Was Not Used
The obvious question is why, if HOCl at slightly acidic pH is the immune system’s primary antimicrobial weapon — if it is the molecule that evolution selected across hundreds of millions of years of optimization — it was not the basis of commercial disinfection technology.
The answer is chemistry and engineering, not conspiracy.
HOCl at slightly acidic pH is inherently unstable. In solution, it equilibrates between its active acidic form and the less active hypochlorite ion. At room temperature and in the absence of specific stabilization conditions, HOCl solutions lose activity over time. Light, temperature, and pH drift all accelerate the degradation. A solution produced today may be significantly less effective tomorrow.
This instability made HOCl unsuitable for the industrial model of disinfection that developed across the twentieth century — a model built around centralized production, extended supply chains, warehouse storage, and retail distribution. A product that degrades in the bottle cannot be manufactured in one location, shipped to a distribution center, stored for weeks, delivered to a retailer, stocked on a shelf, and still be effective when the end user applies it.
Sodium hypochlorite, by contrast, is stable in its alkaline form. Alcohol is stable indefinitely in sealed containers. Quaternary ammonium compounds are stable at room temperature for extended periods. These products were adopted not because they were superior to HOCl but because they were compatible with the industrial model of production and distribution that existed.
The technological constraint that made HOCl impractical for commercial disinfection was not the molecule itself. It was the absence of a production method that could generate HOCl at the point of use, in the concentration and pH range required for maximum efficacy, without the supply chain dependency that instability makes incompatible with centralized distribution.
That production method is the electrolysis of dilute saline or dilute hydrochloric acid solutions at controlled conditions. The electrochemical parameters — current density, flow rate, electrode composition, pH control — determine the ratio of HOCl to OCl⁻ in the output and therefore the biological activity of the product. When controlled precisely, electrolysis produces slightly acidic hypochlorous acid water — HOCl at pH 5.0 to 6.5 — at concentrations sufficient for broad-spectrum microbial kill, at the point of use, without the stabilization chemistry that alkaline hypochlorite solutions require and without the supply chain dependency that degradation makes incompatible with centralized production.
The electrochemical technology to do this at practical scale has been available since the 1970s in research contexts and has been refined across the past three decades into systems that are now deployable at the clinical, food production, agricultural, and household scales. The regulatory frameworks that validate the efficacy and safety of the resulting product have been established in Japan, the European Union, and increasingly in the United States and other markets.
The technological constraint has been resolved. What remains is the institutional lag — the time it takes for a new capability to displace the products, the distribution infrastructure, the professional habits, and the regulatory frameworks that were built around the less optimal alternatives.
The Century of Unnecessary Chemistry
It would be historically inaccurate to describe the past century of commercial disinfection as fraud. The alternatives to HOCl that filled that century were not chosen to deceive. They were chosen because they were available, manufacturable, and effective enough for the contexts in which they were used.
But they were not chosen because they were what the body would have chosen. And the costs of the substitution — the toxicity profiles, the environmental persistence, the development of microbial tolerance, the residue on surfaces and in water systems — are costs that a century of choosing what was manufacturable over what was optimal has accumulated.
The neutrophil does not leave a toxic residue when it kills a bacterium. HOCl in the phagosome degrades when its work is done. The antimicrobial mechanism that the immune system evolved is designed to be effective and then gone — to kill without collateral chemical persistence.
The commercial alternatives are not designed this way. They are designed to be stable — to maintain their antimicrobial activity across the conditions of storage and distribution that centralized production requires. The stability that makes them compatible with the industrial model is achieved through chemical properties that the body’s own mechanism specifically avoided: alkalinity, organic molecular structures that persist in the environment, concentrations that are toxic to biological systems beyond the pathogen being targeted.
A century of using what was manufacturable rather than what the body already knew has produced cleaning products that work — and that also irritate skin, contaminate waterways, select for tolerant microbial populations, and require the ongoing production and distribution of chemical compounds that the body’s own solution renders unnecessary.
What Changes Now
The on-site electrolytic production of slightly acidic hypochlorous acid water changes the constraint that forced the substitution.
The instability of HOCl in solution is not a problem when the solution is produced at the point of use. A system that generates slightly acidic hypochlorous acid water from water and a small amount of salt, on demand, in the concentration and pH range required for maximum efficacy, eliminates the supply chain dependency that instability makes incompatible with centralized production. The product does not need to be stable in a bottle on a shelf. It is produced when it is needed and used immediately.
This is the production model that the body uses. Neutrophils do not stockpile HOCl. They synthesize it at the point of use — inside the phagosome, at the moment of pathogen contact, in the concentration required for the task. The electrochemical systems that now produce HOCl at clinical and commercial scales are doing, at a larger scale, exactly what the neutrophil does at the cellular scale.
The implications extend across every context in which chemical disinfection is currently used. Clinical environments where the toxicity profiles of current disinfectants create occupational exposure concerns. Food production systems where chemical residues on products and in wastewater streams create regulatory and environmental costs. Agricultural contexts where the resistance implications of broad antibiotic and chemical use are producing increasingly serious consequences. Household cleaning where the environmental persistence of commercial cleaning chemicals has become a documented ecological concern.
In each of these contexts, the substitution that made sense when on-site HOCl production was not feasible becomes unnecessary when it is. The body’s solution — the one that evolution selected, that the neutrophil deploys, that degrades without residue and kills without generating resistance — is now producible at the scale and in the contexts where the industrial alternatives currently operate.
The Wisdom That Was Always There
There is a specific kind of knowledge that this archive has returned to across multiple essays — the knowledge that biological systems developed before consciousness existed to name it, that human practice has been slowly and imperfectly rediscovering, and that the tools of modern science are now allowing us to understand with a precision that changes what we can do with it.
The immune system’s use of HOCl is an instance of this pattern.
The neutrophil did not develop its antimicrobial mechanism through deliberate design. It developed it through the same process that produced every other feature of the immune system — variation, selection, retention across hundreds of millions of years of continuous testing against the full diversity of pathogenic life. What it arrived at is not merely effective. It is optimal in the specific sense that selection pressure produces optima: the best available solution to a well-specified problem under realistic operating conditions.
The problem was: how to kill the widest possible range of pathogens quickly, reliably, and without damaging the surrounding tissue of the organism being protected.
The solution was HOCl at slightly acidic pH.
A century of industrial disinfection chemistry approached the same problem with different constraints — how to kill a sufficient range of pathogens reliably enough, using compounds that could be manufactured at scale, stabilized for distribution, and sold at margins compatible with the industrial model.
The solutions it arrived at were not wrong. They were adequate to the constraints. But they were not optimal. They were substitutes for the optimal — manufactured approximations of what the body already knew, deployed because the body’s own solution was not yet manufacturable at commercial scale.
It is now.
The wisdom was always there. In the neutrophil. In the phagosome. In the oxidative burst that the immune system has been deploying against pathogens since long before the first disinfectant was manufactured, the first cleaning product was sold, or the first chemical company was incorporated.
The body already knew how to clean.
We are only now building the tools to listen.
Frequently Asked Questions
What is hypochlorous acid and why does the immune system use it?
Hypochlorous acid (HOCl) is the primary antimicrobial molecule produced by neutrophils — the white blood cells that constitute the body’s first line of defense against bacterial infection. Neutrophils synthesize HOCl through the enzyme myeloperoxidase from hydrogen peroxide and chloride ions, deploying it inside the phagosome — the membrane-enclosed compartment in which engulfed bacteria are destroyed. HOCl kills pathogens through broad-spectrum oxidative disruption of cellular structure, at concentrations simultaneously sufficient for rapid kill and safe for surrounding tissue. Evolution selected this mechanism across hundreds of millions of years of optimization against the full diversity of pathogenic life.
Why did commercial disinfection use other chemicals instead of HOCl?
HOCl at slightly acidic pH — the condition of maximum biological activity — is inherently unstable in solution. It degrades over time with exposure to light, temperature variation, and pH drift. This instability made it incompatible with the centralized production, extended storage, and distribution supply chains of twentieth-century commercial disinfection. The alternatives — alkaline sodium hypochlorite, alcohol, quaternary ammonium compounds — were adopted because they were stable enough for commercial distribution, not because they were superior to what the immune system uses.
What is slightly acidic hypochlorous acid water and how is it produced?
Slightly acidic hypochlorous acid water is an aqueous HOCl solution at pH 5.0 to 6.5, produced through the electrolysis of dilute saline or dilute hydrochloric acid solutions under controlled electrochemical conditions. At this pH, HOCl exists in its most biologically active form — the same form that neutrophils deploy inside the phagosome. On-site electrolytic production eliminates the supply chain dependency that HOCl’s instability makes incompatible with centralized manufacturing, producing the molecule at the point of use in the concentration and pH range required for maximum efficacy.
Why can’t bacteria develop resistance to HOCl?
Antibiotic resistance develops when bacteria evolve specific countermeasures to specific mechanisms of interference with specific metabolic pathways. HOCl does not target a specific metabolic pathway. It disrupts the fundamental structural integrity of bacterial cells through broad-spectrum oxidative assault on cell walls, membrane proteins, enzymatic machinery, and DNA. There is no specific evolutionary countermeasure available to a cell whose structural integrity is being oxidatively destroyed. This is why the immune system’s use of HOCl has remained effective against bacterial diversity across hundreds of millions of years.
What are the environmental implications of switching to HOCl-based disinfection?
Slightly acidic hypochlorous acid water degrades into water and trace saline after use, producing no persistent chemical residue. This contrasts with quaternary ammonium compounds, which are toxic to aquatic organisms and persistent in water systems, and with high-concentration alkaline hypochlorite solutions, which require pH adjustment before discharge. The replacement of these compounds with on-site-produced HOCl in clinical, food production, and household contexts would substantially reduce the volume of synthetic chemical compounds entering water systems through disinfection use.
Is this technology currently available and regulated?
Yes. The electrolytic production of slightly acidic hypochlorous acid water has been regulated and validated in Japan since the 1990s, where it is approved for use in food processing, medical facilities, and agricultural applications. Regulatory frameworks have been established or are under development in the European Union, the United States, and other major markets. The technology is currently deployed at commercial scale in clinical, food production, and agricultural contexts in multiple countries, with expanding adoption as the regulatory frameworks that validate its efficacy and safety profiles mature.
BODY is the archive’s investigation of the biology of a life that lasts.
For those who intend to last.